$Novavax(NVAX)$GAITHERSBURG, Md., Sept. 23, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, with its partner, Serum Institute of India Pvt. Ltd. (SII), today announced a regulatory submission to the World Health Organization (WHO) for emergency use listing (EUL) of Novavax' recombinant nanoparticle protein-based COVID-19 vaccine candidate with Matrix-MTM adjuvant. The submission to WHO is based on the companies' previous regulatory submission to the Drugs Controller General of India (DCGI)."Today's submission of our protein-based COVID-19 vaccine to WHO for emergency use listing is a significant step on the path to accelera
$Novavax(NVAX)$In the U.K., novavax, which is not even approved yet, is going to be in a booster study https://www.gov.uk/government/news/new-study-to-test-third-covid-19-vaccine-for-people-with-weakened-immune-systems
$Novavax(NVAX)$WHO webinar starts August 13 13:00 CET:WHO consultation on COVID-19 vaccines research – 13 August 202113 August 2021 13:00 – 18:00 CETIn continuation to the scientific discussions on COVID-19 vaccines research, WHO R&D Blueprint is organizing a consultation on the state of the art and best research methods to evaluate existing, modified and new COVID-19 vaccines.The objectives of this forthcoming consultation will be to review the available evidence on the efficacy and effectiveness of vaccines being deployed in terms of:Emerging variants effect on protection levels Duration of protectionSafety of booster vaccinesResearch to evaluate various delivery strategieshttps://www.who.int/news-room/events/detail/2021/08/13/default-calendar/
$BioNTech SE(BNTX)$ FDA permits Covid vaccine booster shots for people with weakened immune systemsKEY POINTSThe FDA authorized Covid vaccine booster shots for people with weakened immune systems.Such people – including cancer and HIV patients – in general do not produce an adequate immune response after receiving two doses of a vaccine, U.S. officials say.The agency's move may shield some of the most vulnerable Americans from the highly contagious delta variant.https://www.cnbc.com/2021/08/13/covid-booster-shots-fda-permits-third-dose-for-the-immune-deficient.html
$Novavax(NVAX)$Update From FUJIFILM Diosynth Biotechnologies And Novavax About Their Pandemic Vaccine CandidateThe corporate office of FUJIFILM Diosynth Biotechnologies (FDB) sent WTAW News an update on the development of a pandemic vaccine candidate with Novavax.What FDB describes as “additional required analytical work” is underway.Both companies expect to submit the vaccine candidate for emergency use authorization in the United States sometime between October 1 and the end of this year.The update also says the companies are collaborating to advance commercial manufacturing that involves restarting manufacturing at FDB’s facility in the Bryan/College Station biocorridor.According to the news release, their vaccine candidate has demonstrated a robu